Operating Sales Margin: uniQure Corp (QURE)

Corporate company logo of uniqure.com (QURE)

uniQure N.V. (QURE) is a leading developer of DNA-based drugs investing in viral vectors for the therapy of rare pathologies. The operating profit margin reflects efficiency dynamics, where the -1026.90 level serves as a critical benchmark. A team of elite biologists ensures steady research progress, while unique hemophilia treatment methods guarantee patient loyalty under strict FDA oversight.

uniqure.com (QURE): Operating Profit Rate from 07/04/2022 to 11/20/2026

Analytical breakdowns for uniqure.com (QURE)

- price and consensus price forecast:
- company stock exchange capitalization indicators:
General company analysis:uniQure NV, QURE
Finished products of uniQure N.V.

Operating margin measures the share of profit from core operations before interest and taxes relative to total revenue. By analyzing the operating margin trend, an investor assesses the internal efficiency of cost management. The metric is calculated as the ratio of operating profit to sales, reflecting the profitability of the business core. For uniQure N.V. (QURE), this accounts for the costs of complex logistics for therapeutic vectors. Optimizing redundant routes between the US and Europe directly impacts this indicator.

Main competitors

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability